The 2006 Life Sciences Venture Summit

Title Sponsor

Founding Sponsor

Coaching Sponsor

Platinum Sponsor

Summit Host

Printing Sponsor

Breakfast Sponsor

Contributing Sponsor

Featured VCs

Industry Partners

Life Sciences Venture Summit 2006: Agenda

Wednesday, October 25, 2006
8:00 am	CONFERENCE REGISTRATION & CONTINENTAL BREAKFAST


8:45 am	WELCOME REMARKS
	Joe Benjamin Founder & CEO youngStartup Ventures Bill Fair Managing Director, Healthcare & Biosciences NYC Economic Development Corporation

9:00 am	THE LIFE SCIENCE ROAD MAP – VC OUTLOOK 2007 Life Science VCs, possessing strong industry savvy, are always on the pulse of the newest bioscience frontiers and keenly seek to invest in opportunities that monetize these advancements. Where are Life Science VCs currently focusing? More importantly, where will they be focusing? This panel of seasoned investors will examine the shifting paradigms and trends in drug development and healthcare delivery, and where these trends are heading in 2007. Moderator: Todd Lorenz Partner & Chair of the Life Sciences and Health Care Group Dorsey & Whitney, LLP Panelists: Reinhard J. Ambros Executive Director Novartis Venture Fund Bruce Booth Principal Atlas Ventures Carl S. Goldfischer, MD Managing Director Bay City Capital LLC Ron Hunt Managing Director New Leaf Venture Partners Richard S. Kollender Partner Quaker BioVentures David Mack Director Alta Partners Jim Sherblom Managing General Seaflower Ventures

9:50 am	BREAK

10:00 am	COMPANY PRESENTATIONS – ROUND I Track I : Biotech/Pharma (2nd floor, Crystal Room) Track II: Medical Device/LS/Healthcare IT/Diagnostics (3rd floor, Gramercy Suite)

10:50 am	COMPANY SHOWCASE & NETWORKING BREAK

11:20 am	MEETING THE GRADE Investing equity in emerging companies is a risky business. Therefore, it is vital to know what entices investors to a particular venture. This panel will asses what attracts Life Science VCs, and what emerging companies need to do to meet the grade. Moderator: Antonette Favuzza Senior Member, Emerging Business Group Geller & Company Panelists: Dr. Kevin J. Bitterman Principal Polaris Venture Partners Mary L. Campbell General Partner EDF Ventures Standish Fleming Managing Director Forward Ventures Noah J. Kroloff Principal NGN Capital Ronald W. Lennox Partner CHL Medical Partners Andrew J. Schwab Founder and Managing Partner 5AM Ventures Lee R. Wrubel General Partner Foundation Medical Partners

12:10 pm	BREAK

12:20 pm	COMPANY PRESENTATIONS – ROUND II Track I : Biotech/Pharma (2nd floor, Crystal Room) Track II: Medical Device/LS/Healthcare IT/Diagnostics (3rd floor, Gramercy Suite)

1:10 pm	LUNCH

2:10 pm	FROM PRE-CLINICAL TRIALS TO A GLOBAL PRESENCE: THE LIFECYLCE OF A STARTUP This panel will discuss the various stages in a startups’ life cycle, analyzing the various obstacles and strategies a life science company must encounter and employ from pre-clinical trials to later stage funding. Moderator: Merrill M. Kraines Partner & Co-head of the Technology and Emerging Companies Practice Fulbright & Jaworski LLP Panelists: Suzette Dutch Managing Partner Triathlon Medical Ventures Kent Gossett Principal SR One Jim Gunton General Partner NJTC Venture Fund Arthur Klausner Partner Pappas Ventures Stephen Knight, MD Managing Partner Fidelity Biosciences Sunny Sharma Venture Partner Investor Growth Capital

3:00 pm	BREAK

3:10 pm	COMPANY PRESENTATIONS – ROUND III Track I : Biotech/Pharma (2nd floor, Crystal Room) Track II: Medical Device/LS/Healthcare IT/Diagnostics (3rd floor, Gramercy Suite)

4:00 pm	COMPANY SHOWCASE & NETWORKING BREAK

4:40 pm	WHAT NEXT? STRATEGIES FOLLOWING INITIAL ROUNDS OF FUNDING Following initial rounds of funding, what strategies must be employed to develop the company further? Is it wise to seek a further round or even go to IPO? This panel will evaluate the potential highs and lows following initial investment. Moderator: Maria G. Gotsch Co-Chief Executive Officer and Co-President New York City Investment Fund Panelists: David Azad Principal Galen Partners David F. Hendren Managing Director Catalyst Health & Technology Partners Michael Lytton General Partner Oxford Bioscience Partners Thomas E. Needham, Jr. Principal Advent International Corp. Geoffrey W. Smith Managing Director Ascent BioMedical Ventures

5:30 pm	CLOSING REMARKS - CONFERENCE ADJOURNS
	* Program schedules and speakers are subject to change